Desloratadine

TargetMol
Product Code: TAR-T2520
Supplier: TargetMol
CodeSizePrice
TAR-T2520-25mg25mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2520-50mg50mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2520-1mL1 mL * 10 mM (in DMSO)£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2520-100mg100mg£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2520-200mg200mg£152.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2520-500mg500mg£264.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2520-1g1g£378.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Desloratadine is a long-acting piperidine derivate with selective H1 antihistaminergic and non-sedating properties. Desloratadine diminishes the typical histaminergic effects on H1-receptors in bronchial smooth muscle, capillaries and gastrointestinal smooth muscle, including vasodilation, bronchoconstriction, increased vascular permeability, pain, itching and spasmodic contractions of gastrointestinal smooth muscle. Desloratadine is used to provide symptomatic relieve of allergic symptoms.
CAS:
100643-71-8
Formula:
C19H19ClN2
Molecular Weight:
310.83
Pathway:
GPCR/G Protein; Neuroscience; Immunology/Inflammation; Metabolism
Purity:
0.998
SMILES:
Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1
Target:
Endogenous Metabolite; Histamine Receptor

References

1. 1. Cardel?s I, et al. Eur J Pharmacol. 1999 Jun 18;374(2):249-54. 2. Geha RS, et al. J Allergy Clin Immunol, 2001, 107(4), 751-762. 3. Schroeder JT, et al. Clin Exp Allergy, 2001, 31(9), 1369-1377. 4. Anthes JC, et al. Eur J Pharmacol, 2002, 449(3), 229-237. 5. Howell G 3rd, et al. BMC Pharmacol, 2005, 5, 13. 6. Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382.